Jazz Pharmaceuticals Company Description
Jazz Pharmaceuticals wants to paint the town with successful treatments for niche psychiatric and neurological conditions. The company has several products on the market, including narcolepsy treatment Xyrem (which is also in clinical trials for the treatment of fibromyalgia) and Antizol, an antidote for ethylene glycol and methanol poisoning. The company acquired both drugs through its 2005 purchase of Orphan Medical. Jazz Pharmaceuticals also has US marketing rights for Solvay Pharmaceuticals' Luvox CR, a treatment for obsessive compulsive disorder (OCD) and social anxiety disorder that the FDA approved in 2008.
View the Comprehensive Company Description for Jazz Pharmaceuticals
The Company Description provides a historical perspective of Jazz Pharmaceuticals's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Jazz Pharmaceuticals's evolution in the marketplace.
